StockTipsArenaBeta

BUY Zydus Lifesciences Limited — Kunal Parar, Choice Broking

BUYZydus Lifesciences Limited
Zydus Lifesciences share price target & all analyst calls

byKunal Parar, Choice BrokingHorizon: NA (inferred Swing (≤2wk))25 Aug 2026via ET Now

Entry₹1,127.4Inferred
Target₹1,150
Total upside +2.00% (call closed)
Stop loss₹1,090-3.32% risk
Exit₹1,15026 Aug 2026, 2:50 pm
Target hit+2.00%0.00%upside left
Follow Kunal Parar for new calls(24% target hit, 66 closed calls)Get alertsWatch ZYDUSLIFE for new buy/sell callsGet alertsSee 105 active Swing picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

Frozen at close · 26 Aug 2026
6 supporting1 neutral1 opposing
Supports the BUY call (6)

Zydus Lifesciences Shares Tick Higher On USFDA Nod For Ascorbic Aid Injection

NewsNdtv-Profit·21 Aug · 4d ago

(opens in new tab)

Zydus Lifesciences gets USFDA approval for generic Ascorbic Acid Injection

NewsCnbc-Tv18·21 Aug · 4d ago

(opens in new tab)

Zydus Lifesciences Ltd received final approval from the USFDA for Ascorbic Acid Injection, including 180-days CGT exclusivity.

BSE · Company Update·21 Aug · 5d ago

(opens in new tab)

Zydus Lifesciences Limited's subsidiary, Sentynl Therapeutics, has entered into an option and license agreement with Mereo BioPharma for alvelestat, a potential treatment for Alpha-1 Antitrypsin Defic

NSE · Press Release·11 Aug · 2w ago

(opens in new tab)

Zydus Lifesciences' subsidiary Sentynl Therapeutics has entered into an option and license agreement with Mereo BioPharma for alvelestat, a potential treatment for Alpha-1 Antitrypsin Deficiency-Assoc

BSE · Company Update·11 Aug · 2w ago

(opens in new tab)
Neutral / worth noting (1)

From Zydus Lifesciences To Greenpanel: Check HDFC Securities' Latest Q1 Ratings, Target Prices, Outlook

NewsNdtv-Profit·12 Aug · 2w ago

(opens in new tab)
Weighs against the BUY call (1)

Zydus Lifesciences shares drop 3% after Q1 earnings. Here's why Nuvama upgraded rating, hiked target

NewsEt-Markets·12 Aug · 2w ago

(opens in new tab)

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Zydus Lifesciences

All analyst calls on Zydus Lifesciences

More from Kunal Parar, Choice Broking

Every call and its outcome